13F Holdings
中文EN

ATNM Actinium Pharmaceuticals, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1388320 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY130.6%
TTM EPS YoY130.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE55.2%
ROA23.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets24.3%
Debt / equity0.00x
Current ratio4.00x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-2.20x
Accruals ratio76.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$90,000—$81,000$1.03M$1.14M
Cost of revenue————$900,000
Gross profit————$244,000
R&D expense$21.12M$30.05M$38.67M$23.14M$18.03M
SG&A expense$15.21M$12.08M$13.33M$12.00M$8.08M
Operating income-$36.25M-$42.12M-$51.92M-$34.10M-$24.96M
Pretax income-$33.29M-$38.24M———
Net income-$33.89M-$38.24M-$48.82M-$33.02M-$24.77M
EBITDA-$36.07M-$41.92M-$51.71M-$33.41M-$24.44M
EPS (basic)-1.09-1.27-1.83-1.37-1.20
EPS (diluted)-1.09-1.27-1.83-1.37-1.20
Weighted avg. shares (diluted)31.20M30.07M26.60M24.14M20.57M
Banking
Net interest income——$3.10M$1.09M$190,000
Balance sheet
Cash & equivalents$48.00M$73.23M$76.99M$109.61M$78.22M
Current assets$49.38M$74.51M$78.26M$110.94M$79.75M
PP&E, net$295,000$364,000$550,000$604,000$340,000
Total assets$51.77M$76.90M$81.44M$114.19M$80.39M
Current liabilities$7.97M$8.15M$8.49M$10.63M$6.84M
Total liabilities$43.94M$44.14M$45.07M$47.71M$6.84M
Shareholders' equity$7.83M$32.76M$36.38M$66.48M$73.55M
Shares outstanding31.20M31.20M27.63M25.67M22.14M
Cash flow statement
Operating cash flow-$24.58M-$33.07M-$47.34M$8.64M-$20.87M
Capital expenditure$104,000$11,000$153,000$366,000$133,000
Free cash flow-$24.68M-$33.08M-$47.49M$8.28M-$21.00M
Investing cash flow-$104,000-$11,000-$153,000-$366,000-$133,000
Financing cash flow-$217,000$29.32M$14.87M$23.11M$35.22M
Depreciation & amortization$173,000$197,000$207,000$699,000$524,000
Stock-based compensation$9.19M$5.29M$3.84M$2.79M$1.69M

Free plan shows the latest 5 periods; Pro shows all 25 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.